Akouos’ $244.4 Million IPO


Wilmer Cutler Pickering Hale and Dorr represented Akouos Inc. in its Initial Public Offering.

Akouos, Inc. , a precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for people worldwide who live with disabling hearing loss, announced the closing of its initial public offering of 14,375,000 shares of common stock at a public offering price of $17.00 per share, including 1,875,000 additional shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares, for gross proceeds of $244.4 million, before underwriting discounts and commissions and offering expenses payable by Akouos. All shares were offered by Akouos.

Akouos’s common stock began trading on the Nasdaq Global Select Market under the ticker symbol “AKUS” on June 26, 2020.

BofA Securities, Cowen, and Piper Sandler acted as joint book-running managers for the offering. BTIG acted as lead manager for the offering.

Akouos is a precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for people worldwide who live with disabling hearing loss.

The WilmerHale team was led by Rosemary Reilly (Picture) and Molly Fox.

Involved fees earner: Molly Fox – WilmerHale; Rosemary Reilly – WilmerHale;

Law Firms: WilmerHale;

Clients: Akouos;

Author: Ambrogio Visconti